Contributions
Abstract: P1132
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Heterogeneous clinical presentation, course, and treatment responses of multiple sclerosis (MS) require specific diagnostic and prognostic biomarkers. In a previous study of our group, cerebrospinal fluid (CSF) proteomic analysis of a prospective cohort (N=179) revealed 151 differentially expressed proteins and corresponding affected pathways including sodium reabsorption and notch signalling pathways in different clinical MS subtypes (Avsar, 2015). Current study aimed to confirm and quantify differential expressions of identified proteins separately, and explore related other proteins from the affected pathways from a subset of patients of the same MS cohort. CSF levels of proteins were evaluated by enzyme-linked immunosorbent assay (ELISA) in 30 clinically isolated syndrome (CIS), 30 relapsing-remitting MS (RRMS), 24 primary progressive MS (PPMS) patients, and 20 non-MS controls comprised of patients with non-inflammatory neurologic disorders and other neuro-inflammatory diseases. Phosphatidylinositol 3-kinase (PI3K), and E3 ubiquitin-protein ligase (NEDD4) proteins levels, involved in sodium reabsorption pathway, were significantly increased in CSF samples of CIS patients compared to controls (292.3 µg/ml and 23.4 µg/ml, respectively, 95% CI, 92%, p< 0.01). Notch, nicastrin (NCT), numb-like protein (NUMBL), and presenilin enhancer 2 (PSENEN) proteins from the notch signalling pathway were also evaluated. NUMBL level was decreased in CIS (1621.9 µg/ml, 95% CI, 95%, p< 0.01) and RRMS (1469.8 µg/ml, 95% CI, 95%, p< 0.001) compared to controls and PPMS in CSF samples. CSF PSENEN level was decreased in CIS, RRMS, and PPMS patients compared to controls (1874.7 µg/ml, 2584 µg/ml, 2348.1 µg/ml, 95% CI, 96%, p< 0.0001, p< 0.0001, p< 0.05 respectively). As a result of our initial screening of CSF sodium reabsorption and notch pathways; PI3K, NEDD4, NUMBL and PSENEN proteins appeared as potential biomarkers for differentiating CIS patients from other clinical forms of MS, which require further scrutiny.
Disclosure: Eda Tahir Turanli: nothing to disclose
Timucin Avsar: nothing to disclose
Elif Everest: nothing to disclose
Zeynep Ozturk: nothing to disclose
Eren Sahin: nothing to disclose
Dilem Ceren Oran: nothing to disclose
Melih Tutuncu: nothing to disclose
Sabahattin Saip: nothing to disclose
Ugur Uygunoglu: nothing to disclose
Aksel Siva: nothing to disclose
Abstract: P1132
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Heterogeneous clinical presentation, course, and treatment responses of multiple sclerosis (MS) require specific diagnostic and prognostic biomarkers. In a previous study of our group, cerebrospinal fluid (CSF) proteomic analysis of a prospective cohort (N=179) revealed 151 differentially expressed proteins and corresponding affected pathways including sodium reabsorption and notch signalling pathways in different clinical MS subtypes (Avsar, 2015). Current study aimed to confirm and quantify differential expressions of identified proteins separately, and explore related other proteins from the affected pathways from a subset of patients of the same MS cohort. CSF levels of proteins were evaluated by enzyme-linked immunosorbent assay (ELISA) in 30 clinically isolated syndrome (CIS), 30 relapsing-remitting MS (RRMS), 24 primary progressive MS (PPMS) patients, and 20 non-MS controls comprised of patients with non-inflammatory neurologic disorders and other neuro-inflammatory diseases. Phosphatidylinositol 3-kinase (PI3K), and E3 ubiquitin-protein ligase (NEDD4) proteins levels, involved in sodium reabsorption pathway, were significantly increased in CSF samples of CIS patients compared to controls (292.3 µg/ml and 23.4 µg/ml, respectively, 95% CI, 92%, p< 0.01). Notch, nicastrin (NCT), numb-like protein (NUMBL), and presenilin enhancer 2 (PSENEN) proteins from the notch signalling pathway were also evaluated. NUMBL level was decreased in CIS (1621.9 µg/ml, 95% CI, 95%, p< 0.01) and RRMS (1469.8 µg/ml, 95% CI, 95%, p< 0.001) compared to controls and PPMS in CSF samples. CSF PSENEN level was decreased in CIS, RRMS, and PPMS patients compared to controls (1874.7 µg/ml, 2584 µg/ml, 2348.1 µg/ml, 95% CI, 96%, p< 0.0001, p< 0.0001, p< 0.05 respectively). As a result of our initial screening of CSF sodium reabsorption and notch pathways; PI3K, NEDD4, NUMBL and PSENEN proteins appeared as potential biomarkers for differentiating CIS patients from other clinical forms of MS, which require further scrutiny.
Disclosure: Eda Tahir Turanli: nothing to disclose
Timucin Avsar: nothing to disclose
Elif Everest: nothing to disclose
Zeynep Ozturk: nothing to disclose
Eren Sahin: nothing to disclose
Dilem Ceren Oran: nothing to disclose
Melih Tutuncu: nothing to disclose
Sabahattin Saip: nothing to disclose
Ugur Uygunoglu: nothing to disclose
Aksel Siva: nothing to disclose